RankingsPricing
  1. US-listed companies
  2. CRISPR Therapeutics AG
  3. Raw

CRISPR Therapeutics AGCRSP

Market cap
$4.7B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-23-68-16567-349378-650-154-366
Depreciation and amortization1345918242019
Stock-based compensation1119354466102988187
Other non-cash items, net-----2--121739
Acquired in-process research and development-------3-
Accounts receivable3-1-3000-0200-175
Prepaid expenses and other assets14333-1714-2-23-5
Accounts payable and accrued expenses4-112526385-20-27
Deferred revenue---0-451-1-16-2
Operating lease assets and liabilities----1-01015-2-4
Other liabilities, net-00025-11-5-2010
Net cash used in operating activities---9657-238539-496-260-143
Purchase of property, plant and equipment383718823792
Purchase of in-process research and development-------3-
Investment in equity securities--------23
Purchases of marketable debt securities----5941,5091,4181,0661,463
Maturities of marketable debt securities----715561,1961,4531,208
Net cash (used in) provided by investing activities---31-541-1,035-259375-280
Proceeds from Issuance of Common Stock--307415982213133301
Proceeds from exercise of options and ESPP contributions, net of issuance costs----3438383031
Net cash provided by financing activities--3164311,0162513963332
Effect of exchange rate changes on cash---000-0-00-0
(Decrease) increase in cash--217489237-246-716177-91
Capital Expenditures Incurred but Not yet Paid7-0238210
Equity issuance costs in accounts payable and accrued expenses----100003